De nordiska börserna inledde veckans handel med uppgångar på samtliga huvudindex och fortsatte i linje med förra veckans ...
The pharma industry registered a 7.5% value growth year-on-year for the month of February, with sales of ₹18,781 crore, ...
Och det här läkemedlet hjälper dem genom att lugna ned det här suget efter mat, säger Maria Eklind, medicinsk direktör på Novo Nordisk Sverige. Kändiskur för viktminskning Ozempic har haft en ...
The respiratory segment, often influenced by seasonal factors, registered a 1.1% increase in value but faced a 4.6% decline ...
En lärare i Skåne fråntas lärarlegitimationen efter att ha dömts till fängelse för olika sexualbrott mot barn.
The trial assessed Novo Nordisk’s Saxenda as a monotherapy ... pharmacologic intervention as an adjunctive treatment to medication-assisted therapy (MAT) to reduce the risk of relapse. However, key ...
Danish company Novo Nordisk's membership in a UK pharmaceutical industry body has been restored after a two-year suspension ...
Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.
Novo Nordisk A/S' CagriSema disappointed investors again, but today's update should not have surprised anyone. The flexible dosing protocol in the REDEFINE trials likely led to suboptimal efficacy ...
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight in a recent trial. That figure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback